Valuation: Cogstate Limited

Capitalization 422M 305M 260M 238M 225M 418M 29.15B 2.84B 1.1B 13.83B 1.14B 1.12B 48.04B P/E ratio 2026 *
25.6x
P/E ratio 2027 * 20.4x
Enterprise value 364M 263M 224M 205M 194M 360M 25.14B 2.45B 953M 11.92B 986M 965M 41.43B EV / Sales 2026 *
4.35x
EV / Sales 2027 * 3.66x
Free-Float
50.24%
Yield 2026 *
1.31%
Yield 2027 * 1.6%
1 day+0.40%
1 week+0.81%
1 month+9.73%
3 months+14.29%
6 months-12.98%
Current year+9.73%
1 week 2.27
Extreme 2.27
2.52
1 month 2.26
Extreme 2.26
2.69
Current year 2.01
Extreme 2.01
2.69
1 year 1.21
Extreme 1.21
2.97
3 years 0.8
Extreme 0.795
2.97
5 years 0.8
Extreme 0.795
2.97
10 years 0.16
Extreme 0.155
2.97
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 17/12/1999
Chief Executive Officer - 01/12/2005
Director of Finance/CFO - 01/02/2021
Director TitleAgeSince
Director/Board Member - 01/03/2011
Chairman 67 03/11/2009
Director/Board Member - 20/01/2017
Change 5d. change 1-year change 3-years change Capi.($)
+0.40%+0.81%+89.31%+51.22% 305M
-1.13%-3.77%-17.22%-18.72% 42.69B
+1.39%+5.91%+35.08%+32.18% 35.03B
+1.09%-1.01%+247.95%+463.28% 30.98B
+0.87%-0.77%+12.12%-6.97% 29.22B
+1.05%-2.28%+32.43%+26.70% 27.12B
-0.43%+5.49% - - 14.76B
-3.59%-3.37%+113.03%+4,035.93% 13.03B
+0.60%+0.77%+126.16%+113.55% 12.53B
-0.64%-1.97%+6.67%-2.78% 12.21B
Average -0.04%+1.11%+71.73%+521.60% 21.79B
Weighted average by Cap. +0.16%+0.40%+61.89%+340.67%

Financials

2026 *2027 *
Net sales 83.74M 60.45M 51.55M 47.28M 44.76M 82.94M 5.79B 563M 219M 2.74B 227M 222M 9.54B 95.89M 69.22M 59.04M 54.14M 51.25M 94.98M 6.63B 645M 251M 3.14B 260M 254M 10.92B
Net income 16.52M 11.93M 10.17M 9.33M 8.83M 16.37M 1.14B 111M 43.27M 542M 44.76M 43.81M 1.88B 20.68M 14.93M 12.73M 11.68M 11.05M 20.48M 1.43B 139M 54.15M 678M 56.01M 54.83M 2.35B
Net Debt -58.02M -41.88M -35.72M -32.76M -31.01M -57.47M -4.01B -390M -152M -1.9B -157M -154M -6.61B -70.98M -51.24M -43.7M -40.08M -37.94M -70.31M -4.9B -477M -186M -2.33B -192M -188M -8.08B
Logo Cogstate Limited
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Employees
160
Date Price Change Volume
13/05/26 2.480 $ +0.40% 48,703
12/05/26 2.470 $ -1.20% 112,052
11/05/26 2.500 $ +5.49% 41,123
08/05/26 2.370 $ 0.00% 88,287
07/05/26 2.370 $ -3.66% 101,775
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.470AUD
Average target price
3.175AUD
Spread / Average Target
+28.54%

Quarterly revenue - Rate of surprise